Neurona Therapeutics vs Saluda Medical

Side-by-side comparison of AI visibility scores, market position, and capabilities

Saluda Medical leads in AI visibility (74 vs 35)
Neurona Therapeutics logo

Neurona Therapeutics

EmergingLife Sciences & BioTech

Neural Cell Therapy for Neurological Disorders

Neurona Therapeutics develops interneuron cell therapies derived from human iPSCs to repair dysregulated neural circuits; lead program NRTX-1001 is in Phase 1/2 trials for drug-resistant focal epilepsy;

AI VisibilityBeta
Overall Score
D35
Category Rank
#156 of 198
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
32
Perplexity
34
Gemini
32

About

Neurona Therapeutics is a clinical-stage biotherapeutics company founded in 2013 and headquartered in San Francisco, California, that develops regenerative neural cell therapies for chronic neurological disorders. The company generates specific neuronal and glial cell types from human induced pluripotent stem cells (iPSCs) for transplantation into the nervous system, with the goal of repairing dysfunctional neural circuits that underlie conditions such as epilepsy, chronic pain, and other neurological diseases.

Full profile
Saluda Medical logo

Saluda Medical

LeaderLife Sciences & BioTech

Neuromodulation & Spinal Cord Stimulation

Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.

AI VisibilityBeta
Overall Score
B74
Category Rank
#10 of 198
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
72
Perplexity
68
Gemini
80

About

Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.

Full profile

AI Visibility Head-to-Head

35
Overall Score
74
#156
Category Rank
#10
73
AI Consensus
73
stable
Trend
stable
32
ChatGPT
72
34
Perplexity
68
32
Gemini
80
41
Claude
71
29
Grok
71

Key Details

Category
Neural Cell Therapy for Neurological Disorders
Neuromodulation & Spinal Cord Stimulation
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.